{"entity":{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","aka":["Scott Tagawa"],"tldr":"A cancer doctor at Weill Cornell in New York who has spent two decades testing PSMA-targeted radioactive treatments for prostate cancer, from the first antibody versions through to lutetium-177 PSMA-617.","summary":"Scott Tagawa is a genitourinary medical oncologist who has run early-phase trials of PSMA-targeted radioimmunotherapy since the 2000s, starting with the antibody 177Lu-J591 and continuing through the VISION trial of 177Lu-PSMA-617 (lutetium-177 vipivotide tetraxetan), where he was a co-investigator and author on subsequent safety and PSA-kinetics analyses. He is also a lead investigator on Trop-2-directed antibody-drug conjugate trials (TROPHY-U-01, TROPiCS-04) in urothelial cancer, giving him a cross-cutting view of radioligand and ADC approaches to genitourinary disease.\n\nAt Weill Cornell he directs the Genitourinary Oncology Program and the GU Oncology Research Program, and is the institution's principal investigator for the Alliance for Clinical Trials in Oncology. His group's early J591 dosimetry and fractionation studies helped establish the dose-response relationship for PSMA-targeted radioligand therapy that later informed 177Lu-PSMA-617 dosing.","asOf":"2026-09-22","links":[{"label":"Weill Cornell Medicine: Scott T. Tagawa","url":"https://weillcornell.org/sttagawa"},{"label":"VISION safety analysis, European Urology 2024","url":"https://www.sciencedirect.com/science/article/pii/S0302283824000206"}],"tags":["prostate","PSMA","clinician"],"related":["pluvicto","vision","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Urology, and Director of the Genitourinary Oncology Program, Weill Cornell Medicine / NewYork-Presbyterian","specialisms":["genitourinary medical oncology","PSMA radioligand and radioimmunotherapy","antibody-drug conjugates"],"profiles":[{"label":"Weill Cornell Medicine profile","url":"https://weillcornell.org/sttagawa"},{"label":"Weill Cornell VIVO research profile","url":"https://vivo.weill.cornell.edu/display/cwid-stt2007"}],"papers":[{"title":"Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","journal":"Clinical Cancer Research","year":2013,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3778101/"},{"title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.20.03489"},{"title":"Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer","journal":"European Urology","year":2024,"url":"https://www.sciencedirect.com/science/article/pii/S0302283824000206"}]},"route":"/people/scott-tagawa/","neighbours":{"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"trial":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}